Lundbeck reveals Alzheimer’s drug trial failure
Lundbeck has announced that the first late-stage trial of its experimental Alzheimer’s disease candidate idalopirdine failed to hit its primary targets.
Read More
Tag: idalopirdine
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
